Explore: The Journal of Science and Healing
Volume 1, Issue 6 , Pages 437-445, November 2005

Treatment of Acute Bronchitis in Adults With a Pelargonium Sidoides Preparation (EPs® 7630): A Randomized, Double-Blind, Placebo-Controlled Trial

  • A.G. Chuchalin, MD

      Affiliations

    • Russian Research Institute of Pulmonology, Moscow, Russia
    • Corresponding Author InformationCorresponding author: Address: Russian Research Institute of Pulmonology 11th Parkovaya St. 32/61, Moscow 105077 (Russia)
  • ,
  • B. Berman, MD

      Affiliations

    • University of Maryland, College Park, MD
  • ,
  • W. Lehmacher, PhD

      Affiliations

    • Institute for Medical Statistics, Informatics and Epidemiology of the University of Cologne, Cologne, Germany

Background

Acute bronchitis is a widespread medical problem, and, although predominantly caused by viruses, antibiotics are still prescribed unnecessarily. Therefore, it is of utmost importance to evaluate the use of alternative treatments for acute bronchitis.

Objective

To evaluate the efficacy and safety of a Pelargonium sidoides preparation (EPs 7630 is a registered trademark of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany) compared with placebo in patients with acute bronchitis.

Design

Randomized, double-blind, placebo-controlled trial using a design with planned interim analyses.

Setting

Six outpatient clinics.

Patients

One hundred twenty-four adults with acute bronchitis present ≤48 hours, Bronchitis Severity Score (BSS) ≥five points, and informed consent.

Intervention

EPs 7630 or placebo (30 drops three times daily) for seven days.

Measurements

The primary outcome criterion was the change of BSS on day seven.

Results

The decrease of BSS from baseline to day seven was 7.2 ± 3.1 points with EPs 7630 (n = 64) and 4.9 ± 2.7 points with placebo (n = 60). The 95% confidence interval for the difference of effects between the two treatment groups (EPs 7630 minus placebo) was calculated as (1.21, 3.56) showing a significant improvement of EPs 7630 compared with placebo on day seven (P < .0001). For each of the five individual symptoms, rates of complete recovery were considerably higher in the EPs 7630 group. Within the first four days, onset of treatment effect was recognized in 68.8% of patients in the EPs 7630 group compared with 33.3% of patients in the placebo group (P < .0001). Health-related quality of life improved more in patients treated with EPs 7630 compared with placebo-treated patients. Adverse events occurred in 25 of 124 patients (EPs 7630: 15/64 patients, placebo: 10/60 patients). All adverse events were assessed as nonserious.

Conclusions

EPs 7630 was superior in efficacy compared with placebo in the treatment of adults with acute bronchitis. It may therefore offer an effective alternative for acute bronchitis unless antibiotics are clearly indicated.

Key words:  Acute bronchitis , double-blind , placebo-controlled , clinical trial , EPs 7630 , Pelargonium sidoides preparation , herbal medicine , randomized controlled trial

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1550-8307(05)00378-2

doi:10.1016/j.explore.2005.08.009

Explore: The Journal of Science and Healing
Volume 1, Issue 6 , Pages 437-445, November 2005